Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Dirix, Luc; Takács, István; Jérusalem, Guy; Nikolinakos, Petros; Arkenau, Hendrik‐Tobias; Forero‐Torres, Andres; V. Boccia, Ralph; E. Lippman, Marc; A. Somer, Robert; Šmakal, Martin; A. Emens, Leisha; Hrinczenko, Borys; Jeff Edenfield, W.; S. Gurtler, Jayne; von Heydebreck, Anja; Grote, H.; M. Chin, Kevin; Hamilton, Erika

doi:10.1007/s10549-017-4537-5

Public

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Published in Breast Cancer Research and Treatment • Oct 23, 2017

Authors:

Luc Dirix

István Takács

Guy Jérusalem

Abstract

PURPOSE: Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. METHODS: In a phase 1 trial (JAV...

Subject

Javelin

Avelumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!